Standard Standard

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. / Gliddon, A.E.; Dore, C.J.; Black, C.M. et al.
In: Arthritis and Rheumatism, Vol. 56, No. 11, 01.11.2007, p. 3837-3846.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Gliddon, AE, Dore, CJ, Black, CM, McHugh, N, Moots, R, Denton, CP, Herrick, A, Barnes, T, Camilleri, J, Chakravarty, K, Emery, P, Griffiths, B, Hopkinson, ND, Hickling, P, Lanyon, P, Laversuch, C, Lawson, T, Mallya, R, Nisar, M, Rhys-Dillon, C, Sheeran, T & Maddison, PJ 2007, 'Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.', Arthritis and Rheumatism, vol. 56, no. 11, pp. 3837-3846. https://doi.org/10.1002/art.22965

APA

Gliddon, A. E., Dore, C. J., Black, C. M., McHugh, N., Moots, R., Denton, C. P., Herrick, A., Barnes, T., Camilleri, J., Chakravarty, K., Emery, P., Griffiths, B., Hopkinson, N. D., Hickling, P., Lanyon, P., Laversuch, C., Lawson, T., Mallya, R., Nisar, M., ... Maddison, P. J. (2007). Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and Rheumatism, 56(11), 3837-3846. https://doi.org/10.1002/art.22965

CBE

Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, Camilleri J, Chakravarty K, et al. 2007. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and Rheumatism. 56(11):3837-3846. https://doi.org/10.1002/art.22965

MLA

VancouverVancouver

Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and Rheumatism. 2007 Nov 1;56(11):3837-3846. doi: 10.1002/art.22965

Author

RIS

TY - JOUR

T1 - Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

AU - Gliddon, A.E.

AU - Dore, C.J.

AU - Black, C.M.

AU - McHugh, N.

AU - Moots, R.

AU - Denton, C.P.

AU - Herrick, A.

AU - Barnes, T.

AU - Camilleri, J.

AU - Chakravarty, K.

AU - Emery, P.

AU - Griffiths, B.

AU - Hopkinson, N.D.

AU - Hickling, P.

AU - Lanyon, P.

AU - Laversuch, C.

AU - Lawson, T.

AU - Mallya, R.

AU - Nisar, M.

AU - Rhys-Dillon, C.

AU - Sheeran, T.

AU - Maddison, P.J.

PY - 2007/11/1

Y1 - 2007/11/1

KW - RHEUMATOLOGY

U2 - 10.1002/art.22965

DO - 10.1002/art.22965

M3 - Article

VL - 56

SP - 3837

EP - 3846

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

SN - 0004-3591

IS - 11

ER -